✦ LIBER ✦

3516 POSTER Report of safety analysis in a randomized phase III study comparing S-1 alone with S-1 plus CDDP in advanced gastric cancer (The SPIRITS trial. TS-1 Advanced Gastric Cancer Clinical Trial Group)

✍ Scribed by T. Hara; W. Koizumi; H. Narahara; A. Takagane; T. Akiya; M. Takagi; K. Miyashita; T. Nishizaki; O. Kobayashi

Book ID: 118625861
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)71019-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S-1 plus cisplatin versus S-1 alone for

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

✍ Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Aki 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 155 KB

Randomized phase III study comparing the

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

✍ Hiroyuki Narahara; Hiroyasu Iishi; Hiroshi Imamura; Akira Tsuburaya; Keisho Chin 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 415 KB

## Background Irinotecan hydrochloride and S-1, an oral fluoropyrimidine, have shown antitumor activity against advanced gastric cancer as single agents in phase I/II studies. The combination of irinotecan and S-1 (IRI-S) is also active against advanced gastric cancer. This study was conducted to c

6509 5-FU/l-LV (RPMI) versus S-1 as firs

6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)

✍ Sawaki, A.; Yamaguchi, K.; Nabeya, Y.; Sakai, Y.; Osanai, H.; Denda, T.; Furue, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Impact of excision repair cross-compleme

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912

✍ Yamada, Y.; Boku, N.; Nishina, T.; Yamaguchi, K.; Denda, T.; Tsuji, A.; Hamamoto 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 160 KB

6521 POSTER Prospective Randomized Contr

6521 POSTER Prospective Randomized Controlled Phase II Trial of Alternate-day Vs Consecutive-day Treatment With S-1 as Postoperative Adjuvant Therapy for Gastric Cancer: San-in Clinical Oncology Group Study No. 9

✍ Tsujitani, S.; Tatebe, S.; Ikeguchi, M.; Maehara, Y. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

P.39 Docetaxel plus epirubicin (DE) vs d

P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB